Aims
Insulin degludec/aspart (IDegAsp) and insulin glargine U300 (IGlarU300) have recently emerged as popular new‐generation insulin analogues. The aim of this real‐life study was to investigate the patient profiles in which IGlarU300 and IDegAsp were preferred and the insulin combinations after which each of them were mostly used and also to analyse the effect of these two insulin analogues on blood glucose regulation and hypoglycaemia.
Materials and Methods
The retrospective study included 174 patients that were switched from basal insulin, basal‐bolus insulin, or premixed insulin to IGlarU300 or IDegAsp due to uncontrolled blood glucose levels or history of hypoglycaemia. Hypoglycaemia, body weight, body mass index (BMI), fasting plasma glucose (FPG) and HbA1c levels over 3‐month periods were evaluated for each patient.
Results
There were 84 and 90 patients in the IGlarU300 and IDegAsp groups, respectively. Body weight was similar in both groups. Baseline FPG and HbA1c levels in the IGlarU300 and IDegAsp groups were 9.0%, 175.5 mg/dL and 9.4%, 193.5 mg/dL, respectively. A significant decrease was found in FPG and HbA1c levels in both groups (138.5, 7.8 vs 141.5, 8.2; P < .001 for all). Moreover, a significant weight gain was observed in both groups (P < .05 for both). The prevalence of hypoglycaemia in both groups decreased significantly and consistently between months 1 and 9 (P < .001). At month 12, although this decrease continued in the IGlarU300 group (P = .013), no significant decrease was observed in the IDegAsp group (P = .057).
Conclusion
Both twice‐daily IDegAsp ± bolus insulin and IGlarU300 basal bolus insulin therapies are effective and safe treatment modalities.
Aims/Introduction: Insulin Degludec/Aspart (IDegAsp) and Insulin
Glargine U300 (IGlarU300) have recently emerged as popular
new-generation insulin analogs. The aim of this real-life study was to
investigate the patient profiles in which IGlarU300 and IDegAsp were
preferred and the insulin combinations after which each of them were
mostly used, and also to analyze the effect of these two insulin analogs
on blood glucose regulation and hypoglycemia. Materials and Methods: The
retrospective study included 174 patients that were switched from basal
insulin, basal+bolus insulin, or premixed insulin to IGlarU300 or
IDegAsp due to uncontrolled blood glucose levels or history of
hypoglycemia. Hypoglycemia, body weight, body mass index (BMI), fasting
blood glucose (FBG), and HbA1c levels over three-month periods were
evaluated for each patient. Results: There were 84 and 90 patients in
the IGlarU300 and IDegAsp groups, respectively. Body weight was similar
in both groups. Baseline FBG and HbA1c levels in the IGlarU300 and
IDegAsp groups were 9.0%, 175.5 mg/dl and 9.4%, 193.5 mg/dl,
respectively. A significant decrease was found in FBG and HbA1c levels
in both groups (138.5, 7.8 vs. 141.5, 8.2; p<0.001 for all).
Moreover, a significant weight gain was observed in both groups
(p<0.05 for both). The prevalence of hypoglycemia in both
groups decreased significantly and consistently between month 1 and 9
(p<0.001). At month 12, although this decrease continued in
the IGlarU300 group (p=0.013), no significant decrease was observed in
the IDegAsp group(p=0.057). Conclusion: Both twice-daily IDegAsp±bolus
insulin and IGlarU300+bolus insulin therapies are effective and safe
treatment modalities.
Introduction: We aimed to see whether insulin glargine U300 can provide better blood glucose control while reducing hypoglycaemia in a more homogeneous population compared to previous studies. Material and methods: The retrospective study included type 1 diabetes mellitus (T1DM) patients with frequent hypoglycaemia. For evaluation of fasting blood glucose, haemoglobin glycated (HbA 1c ) and weight at 6 months and 12 months (final), observation windows of 120-240 days (4-8 months) and 240-480 days (9-16 months) after insulin glargine U300 initiation, respectively, were permitted. Mean follow-up time was 12 months. Hypoglycaemia was defined as blood glucose level < 70 mg/dl, either symptomatic or asymptomatic, measured in hospital or at home. Results: Forty-four patients were included in the study, and 35 patients completed the study -20 (57.1%) females and 15 (42.9%) males, with a mean age of 24.1 ±6.6 years. Mean body mass index was 24.4 ±7.4 kg/m 2 . A significant decrease was not found between baseline and HbA 1c values at 6 months (p = 0.199), but a significant decrease was found in the final period (between 9-16 months) (p = 0.025). Hypoglycaemic events occurred in all patients (100%) before using insulin glargine U300, while the incidence of hypoglycaemic events gradually decreased to 74.3%, 68.6%, and 68.6% between months 1-3, 3-6, and 6-9, respectively. Of the 26 patients who declared their level of satisfaction, 23 (88.5%) were satisfied, 2 (7.7%) indicated that there was no significant difference, and 1 (3.8%) patient was unsatisfied. Conclusions: Over 9-16 months of follow-up, insulin glargine U300 led to a significant reduction not only of HbA 1c levels but also of the frequency of hypoglycaemia, and also yielded high satisfaction rates.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.